FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease
- PMID: 39239058
- PMCID: PMC11374260
- DOI: 10.1097/MS9.0000000000002409
FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease
Conflict of interest statement
The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest. The authors declare that they have no conflicts of interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
References
-
- FDA News Release. 8 Dec 2023. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. U.S. Food and Drug Administration. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-g...
-
- Leibovitch JN, Tambe AV, Cimpeanu E, et al. . l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope? Blood Rev 2022;53:100925. - PubMed
-
- Sickle Cell Disease. 15 May 2024. Data and Statistics on Sickle Cell Disease. U.S. Centers for Disease Control and Prevention, CDC. https://www.cdc.gov/sickle-cell/data/index.html
Publication types
LinkOut - more resources
Full Text Sources